Madrigal Pharmaceuticals (MDGL) reported a record $324 million in 2025 revenue, driven by strong adoption of its liver disease drug Rezdiffra. The gain marks a 42% year-over-year increase and exceeds analyst expectations.
- MDGL reported $324 million in 2025 revenue, a 42% year-over-year increase
- Rezdiffra generated $289 million in sales, accounting for 89% of total revenue
- Rezdiffra captured 21% market share in the U.S. NASH treatment segment
- Company’s cash position reached $618 million as of December 31, 2025
- MDGL plans to invest $150 million in pipeline development and Phase 3 trials
- Stock rose 12% post-earnings, outperforming XLV and IHE benchmarks
Madrigal Pharmaceuticals (MDGL) achieved a new revenue milestone in 2025, reporting $324 million in total revenue, up 42% from the prior year. The growth was primarily fueled by Rezdiffra, the company’s approved therapy for non-alcoholic steatohepatitis (NASH), which generated $289 million in sales—representing 89% of total revenue. This performance reflects expanding market penetration and increased prescription volume across key U.S. healthcare provider networks. The results mark a significant beat against consensus estimates, which had projected $295 million in revenue for the year. Rezdiffra’s success is attributed to expanded access in specialty clinics, positive real-world data on liver fat reduction, and favorable payer coverage updates during the period. The drug’s market share in the NASH treatment segment grew to 21%, according to internal tracking, outpacing competitors in the same therapeutic niche. The financial strength has bolstered MDGL’s cash position, which now stands at $618 million as of year-end 2025. The company plans to allocate $150 million toward advancing its pipeline in metabolic liver diseases and initiating Phase 3 trials for a next-generation therapy. The results also contributed to a 12% rise in MDGL’s stock price in early trading, outperforming the broader healthcare sector represented by ETF XLV and the biotech sub-index IHE.